Q&A with Hans Engels, Business Unit President and CEO of DSM Pharmaceuticals - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Hans Engels, Business Unit President and CEO of DSM Pharmaceuticals

Pharmaceutical Technology
Volume 33, Issue 11

PharmTech:




What is the biggest industry challenge you're now facing?

Engels:

With the complexity we have in the supply chain for pharmaceutical products, it is absolutely necessary that the different elements of the supply chain interact much closer together than they have done in the past. Previously, a large pharmaceutical company controlled everything from the top down. By having enough excess capacity in all elements of the supply chain, they were able to fulfill the paradigm of always having product available in the marketplace.

Now this is going away. Now you have high-performing elements in your network that might be your own facility or might be somebody else's facility. You need to make sure that the information exchange between these elements in the network is flawless so that if there is any problem in one element of the network, everybody else becomes aware of it and can take appropriate action. The paradigm is still that product has to be available at all times in the marketplace. If you don't have product, that's the most costly failure you can have.

PharmTech:

A lot of people talk about just-in-time manufacturing, but do you think many pharmaceutical companies are actually trying to do it?

Engels:

If you want to apply it in the pharmaceutical industry, a lot of minds have to change. I think the pharmaceutical industry is far away from on-demand manufacturing for multiple reasons. One of the reasons is the culture of the industry, other reasons are compliance constraints. But I think this should not prevent us from getting as close as possible to that paradigm.

PharmTech:

Has DSM tried new ways of exchanging information with its clients?

Engels:

Yes. For instance, the whole supply chain must know about the progress of deviations in the quality system. We created a dashboard that tracks deviation handling throughout manufacturing, quality assurance, and the laboratories. Because we have not found a way to directly and securely tie clients into our systems, we created data rooms that are automatically updated so the customer can see data we have agreed upon up front that they want to see.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
7%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology,
Click here